116 related articles for article (PubMed ID: 16327162)
1. Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies.
Zhang Y; Zhang Q; Sun Y; Sun J; Wang X; Chen M
Biol Pharm Bull; 2005 Dec; 28(12):2263-7. PubMed ID: 16327162
[TBL] [Abstract][Full Text] [Related]
2. [Degradation of recombinant hirudin-2 in nasal mucosa of rabbits in vitro].
Zhang YJ; Wu JM; Zhang Q; Chen MX; Sun WJ
Yao Xue Xue Bao; 2006 Nov; 41(11):1099-103. PubMed ID: 17262955
[TBL] [Abstract][Full Text] [Related]
3. [Promoting mechanism of enhancers and transport pathway of large hydrophilic molecular across nasal epithelium studied by ESR and CLSM technologies].
Zhang YJ; Zhang Q; Yang J; Sun MJ; Wang XL; Chen MX; Wang Q; Jiang H
Yao Xue Xue Bao; 2007 Nov; 42(11):1195-200. PubMed ID: 18300478
[TBL] [Abstract][Full Text] [Related]
4. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
[TBL] [Abstract][Full Text] [Related]
5. Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo.
Zhang YJ; Ma CH; Lu WL; Zhang X; Wang XL; Sun JN; Zhang Q
Acta Pharmacol Sin; 2005 Nov; 26(11):1402-8. PubMed ID: 16225765
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal absorption of recombinant hirudin-2 in rats.
Yan X; Wang X; Zhang X; Zhang Q
J Pharmacol Exp Ther; 2004 Feb; 308(2):774-9. PubMed ID: 14610232
[TBL] [Abstract][Full Text] [Related]
7. [Preparation of freeze-dried powder of recombinate hirudin-2 nanoparticle for nasal delivery and permeability through nasal membrane in vitro].
Chen MX; Zhang JB; Yu JP; Ye J; Wei BH; Zhang YJ
Zhong Yao Cai; 2013 Jun; 36(6):999-1002. PubMed ID: 24380289
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes.
Liu Y; Lu WL; Zhang X; Wang XQ; Zhang H; Zhang Q
Peptides; 2005 Mar; 26(3):423-30. PubMed ID: 15652649
[TBL] [Abstract][Full Text] [Related]
9. Investigation on recombinant hirudin via oral route.
Cen X; Ni J; Tan T; Liu X; Li C; Chen J; Huang Y; Zhu S; Bi Q
Peptides; 2006 Apr; 27(4):836-40. PubMed ID: 16469415
[TBL] [Abstract][Full Text] [Related]
10. Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes.
Meng M; Liu Y; Wang YB; Wang JC; Zhang H; Wang XQ; Zhang X; Lu WL; Zhang Q
J Control Release; 2008 Jun; 128(2):113-9. PubMed ID: 18423766
[TBL] [Abstract][Full Text] [Related]
11. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization.
Liu Y; Lu WL; Wang JC; Zhang X; Zhang H; Wang XQ; Zhou TY; Zhang Q
J Control Release; 2007 Feb; 117(3):387-95. PubMed ID: 17207884
[TBL] [Abstract][Full Text] [Related]
12. [Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats].
Zhang YJ; Wang XL; Wu JM; Cheng MX
Zhongguo Zhong Yao Za Zhi; 2007 May; 32(9):801-4. PubMed ID: 17639978
[TBL] [Abstract][Full Text] [Related]
13. [Studies on the nasal epithelium toxicity of adjuvants and recombination hirudin (rHV2) nasal spary].
Zhang YJ; Hou JL; Ma CH; Wang XL; Chen MX; Zhang Q
Zhongguo Zhong Yao Za Zhi; 2005 Jun; 30(11):821-4. PubMed ID: 16110860
[TBL] [Abstract][Full Text] [Related]
14. [Absorption of recombinant hirudin in rats GI tract].
Yan XY; Zhang XN; Zhang Q
Yao Xue Xue Bao; 2004 Jan; 39(1):77-80. PubMed ID: 15127588
[TBL] [Abstract][Full Text] [Related]
15. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
[TBL] [Abstract][Full Text] [Related]
16. Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs.
Iyer L; Shavit J; Koza M; Calabria R; Moran S; Fareed J
Thromb Res; 1993 Jan; 69(1):59-70. PubMed ID: 8465275
[TBL] [Abstract][Full Text] [Related]
17. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
Freund M; Cazenave JP; Courtney M; Degryse E; Roitsch C; Bernat A; Delebassée D; Defreyn G; Maffrand JP
Thromb Haemost; 1990 Apr; 63(2):187-92. PubMed ID: 2363120
[TBL] [Abstract][Full Text] [Related]
18. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies.
Yu S; Zhao Y; Wu F; Zhang X; Lü W; Zhang H; Zhang Q
Int J Pharm; 2004 Aug; 281(1-2):11-23. PubMed ID: 15288339
[TBL] [Abstract][Full Text] [Related]
19. Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation.
Zaki NM; Mortada ND; Awad GA; Abd ElHady SS
Int J Pharm; 2006 Dec; 327(1-2):97-103. PubMed ID: 16959453
[TBL] [Abstract][Full Text] [Related]
20. [Effect of absorption enhancers on nasal ginsenoside Rg1 delivery and its nasal ciliotoxicity].
Chen XM; Zhu JB; Sun WD; Zhang LJ
Yao Xue Xue Bao; 2006 Feb; 41(2):149-55. PubMed ID: 16671546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]